InnoCan Pharma (HAM:IP40) Other Financing: €0.06 Mil (TTM As of Mar. 2026)


HAM:IP40 InnoCan Pharma Corp HAM:IP40
62 GF Score
Price €1.63
GF Value €9.62
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Other Financing?

InnoCan Pharma HAM:IP40 +6.19% 62 Other Financing is €0.06 Mil as of Mar. 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 62/100 and a GF Value™ of €9.62 (Possible Value Trap). The stock has 2 warning signs investors should review.

InnoCan Pharma's Other Financing for the three months ended in Mar. 2026 was €0.00 Mil.

InnoCan Pharma's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €0.06 Mil.

InnoCan Pharma Other Financing Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma Other Financing Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 10.11 0.13 1.27 1.75 0.36

InnoCan Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.06 0.00 0.00 0.00
HAM:IP40
62GF Score
InnoCan Pharma Corp HAM:IP40
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0.06 Mil mean?
InnoCan Pharma (HAM:IP40) has a Other Financing of €0.06 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for InnoCan Pharma and its competitors.
Is InnoCan Pharma's Other Financing too high?
InnoCan Pharma's current Other Financing is €0.06 Mil. Overall, InnoCan Pharma has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Other Financing compare to PG and CL?
InnoCan Pharma's Other Financing of €0.06 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Consumer Packaged Goods company?
A good Other Financing depends on the Consumer Packaged Goods industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for InnoCan Pharma and its competitors. InnoCan Pharma's current Other Financing is €0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.62, compared to a current price of €1.63 — trading 83.1% below its estimated fair value. The current Other Financing is €0.06 Mil. InnoCan Pharma's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Other Financing is €0.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.63 is trading 83.1% below its estimated GF Value™ of €9.62. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for HAM:IP40:

  • Other Financing: €0.06 Mil
  • GF Value™: €9.62 vs. price of €1.63 (83.1% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Other Exchanges INNPF:USAINNO:Canada
Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
62GF Score

Get the complete analysis for HAM:IP40

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.63
Price
€9.62
GF Value